Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

Solid phase assay for detecting biomarkers for cardiodiabetes
The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes..

Explant assay to determine the potential for compositions to promote or to inhibit neural tube defects
An explant assay based on embryonic tissue from laboratory animals may be used to identify substances that promote neural tube defects—teratogens to be avoided in pregnancy, and substances that inhibit neural tube defects—supplements that might be taken with benefit during pregnancy—to help reduce the incidence of birth defects. The assay screens for compounds that improve or impede mesodermal cell migration from an explant containing the primitive streak and parts of the lateral mesodermal wings that have been dissected from the embryo of a mouse or other experimental animal.

Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
Provided are methods for detecting and treating disease states, including cancer, diabetes, fibrosis, and autoimmune diseases, by detecting increased mechanical modulus, or stiffness, or targeting tissues having increased mechanical modulus, or stiffness. Practicing these methods provides specific and localized detection assays and therapies for these disease states.

Glucagon-like-peptide-2 (glp-2) analogues
Glp-2 analogues are disclosed which comprise one of more substitutions as compared to h[gly2]glp-2 and which may have the property of an altered glp-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes..

Peptides having reduced toxicity that stimulate cholesterol efflux
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.

New thienopyrimidine derivatives as nik inhibitors
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..

Triazole derivativesas p2y14 receptor antagonists
Described are compounds, which are antagonists of the p2y14 receptor, for example, a compound of formula (i) in which ring a, r1, r2, r3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing p214 receptor activity in a cell..

Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end.

Tetrahydro-isohumulone derivatives, methods of making and using
The present application provides novel tetrahydro-isohumulone (thiaa) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate pparγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to pparγ modulation such as diabetes..

Diabetes management system with automatic basal and manual bolus insulin control
Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller.

Methods and compositions for treatment of metabolic disorders

The present invention relates to the discovery that increases in invariant nkt cell (inkt) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing inkt activity..

Hydrogel composition and associated use

The invention provides a composition and pharmaceutical formulation including a peptide immobilized in a hydrogel. Compositions and formulations of the invention are useful in reducing the size, severity or duration of a wound, ameliorating of one or more symptoms associated with a wound without necessarily curing the wound, or lessening in the growth or severity of a wound.

Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient

The present invention relates to a composition for preventing and treating metabolic disorders, containing a water extract of pleurotus eryngii var. Ferulea (pf) as an active ingredient, wherein the water extract of pleurotus eryngii var.

Compositions and methods for diagnosis and treatment of metabolic syndrome

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..

Electroporation for obesity or diabetes treatment

Endolumenal devices and methods can be used for the treatment of health conditions including obesity and diabetes. In some embodiments, the methods and systems provided herein can cause weight loss or control diabetes by reducing the caloric absorption of an individual.

Systems and methods for managing chronic disease using analyte and patient data

Devices, systems, and methods herein relate to managing a chronic condition such as diabetes. These systems and methods may obtain patient data from a plurality of devices, integrate the data for analysis of trends that may be presented to the patient and/or health care professional along with an actionable suggestion.

Legume/grain based food product with prebiotic/probiotic source

A minimally processed ready-to-eat legume/grain product is provided containing a significant amount of prebiotic fiber and a probiotic source or is consumed with a probiotic source for the prevention and/or treatment of inflammatory chronic conditions such as inflammatory, autoimmune chronic conditions such as irritable bowel syndrome (ibs), digestive disorders such chronic constipation, gastric acid reflux, diabetes, heart disease, obesity, some type of cancer, malabsorptive disorders, eczema as well mental health disorders such as anxiety disorder. The present invention is suitable for men and woman of all ages..

Biomimetic amniotic membrane niche for stem cells

In this invention we propose a method to compose a stem cell culture niche platform, which is based on the use of the human amniotic membrane. Fluid dynamic, mechanical and topographic factors are additionally included in this niche to provide various factors essential for achieving an enhanced biomimetic microenvironment of the cultured stem cells.

Insulins with polar recombinant extensions

The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes..

Cell-permeable (cp)-delta socs3 recombinant protein and uses thereof

The present invention is related to development of the improved cell-permeable (cp)-Δsocs3 recombinant protein which disrupt the interaction of leptin receptor (obr) and suppressor of cytokine signaling 3 (socs3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.. .

Total synthesis of glucosepane and compounds obtained therefrom

Glucosepane is a structurally complex protein post-translational modification (ptm) believed to exist in all living organisms. Research in humans suggests that glucosepane plays a critical role in the pathophysiology of both diabetes and human aging; yet comprehensive biological investigations of this ‘metabolite have been’ greatly hindered by a scarcity of chemically homogeneous material available for study.

Aryl acylsulfonamides as blt1 antagonists

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer..

Compositions and methods for the treatment of metabolic and related disorders

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin a and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an a-b-c tripartite structure, wherein a, b, and c are identical or non-identical structures and are described in detail herein.

Monocarboxylate transport modulators and uses thereof

The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, obesity, diabetes, cardiovascular diseases, tissue and organ transplant rejection, and malaria.. .

Traditional chinese medicine composition for treating psoriasis

The present invention discloses a traditional chinese medicine composition for treating psoriasis, the traditional chinese medicine composition is prepared from materials in the following parts by weight: 5-15 parts of paeoniae radix rubra (red peony root), 3-9 parts of curcumae rhizoma (rhizoma zedoariae), 10-20 parts of sarcandrae herba (sarcandra glabra), 10-20 parts of smilacis glabrae rhizoma (glabrous greenbrier rhizome), 5-15 parts of mume fructus (black plum). The invention has the beneficial effects that the therapeutic effect can be achieved at a small dosage, the toxicity is significantly reduced, the onset is rapid, and the recurrence can be delayed.

Treatment of adipocytes

The present disclosure provides compositions comprising a lyn kinase activator and trpm8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, syndrome x, obesity, prediabetes, type ii diabetes, type i diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.. .

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..

Flavonolignans for treatment of autoimmune inflammatory diseases

A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome.

Detection systems using fingerprint images for type 1 diabetes mellitus and type 2 diabettes mellitus

Methods and kits for determining a propensity to develop type 1 diabetes mellitus (t1dm) and for type 2 diabetes mellitus (t2dm) in an individual by measuring an asymmetry of at least one captured fingerprint from the individual are described.. .

Diabetes management systems, methods and user reminders, pattern recognition, and interfaces

Systems, methods, and apparatus for diabetes management include a portable diabetes management system (dms) device. The dms device includes a processor, a data storage device, a touchscreen display, and wireless communications facilities.

Microenvironments for self-assembly of islet organoids from stem cells differentiation

Human pluripotent stem cells (hpscs) are promising cell source to produce therapeutic endocrine cells for diabetes treatment. A gel solution made by decellularized tissue-specific extracellular matrix (dpecm) significantly promotes three-dimensional (3d) islet-like organogenesis during induced hpsc differentiation into endocrine lineages.

Insulin analogs and use thereof

An insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.. .

Maintaining maximum dosing limits for closed loop insulin management systems

A system and a method for management of diabetes are provided. The system includes an infusion pump, glucose sensor, and controller that is programmed to control insulin delivery based upon at least one stored variable.

Pharmaceutical formulations of desmopressin

Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material.

Use of l. reuteri for recovery of microbiota dysbiosis in early life

The invention concerns lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of actinobacteria and increased levels of proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Methods and compositions for oral administration

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.. .

Influenza virus and type 1 diabetes

Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction.
Istituto Zooprofilattico Sperimentale Delle Venezie

Antibacterial and protective bacteriophage formulations and methods for making and using them

Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel.
San Diego State University (sdsu) Foundation Dba San Diego State University Research Foundation

Insulin secreting polypeptides

This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided..
Mayo Foundation For Medical Education And Research

Diabetes gene therapy

There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of seq id no. 1.
Ucl Business Plc

Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Embodiments of the technology described herein are based, in part, upon the discovery that netosis, the formation of neutrophil extracellular traps (nets) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and net associated complications in diabetes are provided.
The Children's Medical Center Corporation

Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and adhd), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type ii. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising bifidobacterium bifidum w23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement..
Winclove Holding B.v.

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustee Of Columbia University In The City Of New York

Treatment for diabetes in patients inappropriate for metformin therapy

The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.. .
Boehringer Ingelheim International Gmbh

Compositions and methods for treating age-related diabetes and related disorders

The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting ftreg cells with an anti-st2 antibody to decrease age-related ftreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders..
Salk Institute For Biological Studies

Viral vectors for the treatment of diabetes

They are provided gene constructs comprising a nucleotide sequence encoding the insulin-like growth factor 1 (igf-1) of a mammal; and target sequences of a microrna of a tissue where the expression of igf-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them.
Universitat Autonoma De Barcelona

Glycated cd59 peptides, their preparation, and uses thereof

The present invention provides glycated amadori products of the cd59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated amadori products of cd59 and fragments thereof to be used for the generation of antibodies and antibody fragments.
President And Fellows Of Harvard College

Vitamin d3 derivatives and pharmaceutical use thereof

The present invention relates to vitamin d3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.. .
National University Corporation Tokyo University Of Agriculture And Technology

Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use

The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors.
Strongbridge Ireland Limited

Bromocriptine formulations

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes..
Veroscience Llc

Methods of treating conditions related to the s1p1 receptor

Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (s1p1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (r)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type i diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.. .
Arena Pharmaceuticals, Inc.

In vitro identifying a pregnancy related disease

The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (gcf). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby..

Gip peptide analogues

Provided herein are glucose-dependent insulinotropic polypeptide (gip)-derived peptide analogues, for example gip(3-30), and their use as antagonists of the gip receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.. .

Heteroaryl compounds and methods of use thereof

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..

Plant extracts with anti-diabetic and other useful activities

This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling.

Edible composition

Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to node et al.

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..

Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline hba1c

The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months.

Nitrated-fatty acids modulation of type ii diabetes

Nitro oleic acid and related metabolites are agonists of ppar-γ. Surprisingly, nitro oleic acid is a more potent agonist of ppar-γ, relative to nitro linoleic acid.
Klemm+sohn Gmbh & Co. Kg

Double-acylated glp-1 derivatives

The invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 27 of glp-1(7-37) (seq id no: 1); a second k residue at a position corresponding to position t of glp-1(7-37), where t is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to glp-1(7-37); wherein the first k residue is designated k27, and the second k residue is designated kt; which derivative comprises two albumin binding moieties attached to k27 and kt, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from hooc—(ch2)2—co— and hooc—c6h4—o—(ch2)y—co—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —nh—(ch2)2—(o—(ch2)2)k—o—(ch2)n—co—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel glp-1 analogues.
Novo Nordisk As

1-sulfonamido-4-aryloxy compounds, and preparation method and medicinal application thereof

Compounds of formula (i) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of nrf2 by keap1, thereby activating nrf2.
China Pharmaceutical University

Trifunctional and completely clearable specific targeting agents and methods thereof

The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates..
University Of Massachusetts

Colorometric sensor for the non-invasive screening of glucose in sweat in pre and type 2 diabetes

Described here are patches and methods for measuring glucose in sweat (and tears and the like). In general, the patches comprise an adhesive layer adapted to bond to skin of an individual, a substrate layer disposed over the adhesive layer and comprising a glucose sensing complex including a chromogen that changes color in the presence of certain concentrations of glucose, and a cover.
Medtronic Minimed, Inc.

Methods and compositions of short small hairpin rnas and micrornas for wound healing

Wound healing is a complex homeostatic process in which several distinct types coordinate to repair a physical damage. Failure to close wounds contributes to the pathology of conditions like diabetes mellitus, particularly in the elderly.
Somagenics, Inc.

Method for generating beta cells

The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells. The present invention also relates to an isolated population comprising pancreatic progenitor cells or a insulin-producing cells, compositions and their use in the treatment of diabetes.
New York Stem Cell Foundation, Inc.

Antibodies that recognize iapp

The invention provides monoclonal antibody 3h6 and related antibodies. The 3h6 antibody binds to an epitope within residues 28-36 of iapp.
Prothena Biosciences Limited

Composition for treating diabetes or diabesity comprising oxyntomodulin analog

Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a glp-1 receptor and a glucagon receptor, than native oxyntomodulin.
Hanmi Pharm. Co., Ltd.

Aldose reductase inhibitors and methods of use thereof

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like..
The Trustees Of Columbia University In The City Of New York

Chemical compounds

The compounds of the invention are inhibitors of perk and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, huntington's disease, creutzfeldt-jakob disease, fatal familial insomnia, gerstmann-sträussler-scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (cte), neurodegeneration, dementias, frontotemporal dementias, tauopathies, pick's disease, neimann-pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention.

Azetidine compounds as grp119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present disclosure relates to azetidine compounds. The azetidine compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Devices for and methods of treatment of metabolic syndromes

Devices for and methods of treatment of metabolic syndromes are disclosed. Namely, the presently disclosed devices and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic syndromes.
The Johns Hopkins University

Fast-acting insulin composition comprising a citric acid salt

In embodiments, the present disclosure provides an aqueous pharmaceutical composition that includes insulin in hexameric form, and citric acid or a salt thereof at a concentration from 6 to 30 mm, wherein the composition is suitable for injecting into a diabetic patient to treat diabetes.. .
Adocia

Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis

Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (als) by inhibiting igg-mediated activation of voltage-gated calcium channels (vgccs) in cells of the subject, by one or more of removing igg from blood of the subject, blocking igg from activating vgccs in the subject; or blocking vgccs in the subject are described, as are methods for identifying als patients at risk of developing diabetes.. .
Biocrine Ab

Dna vaccines encoding heat shock proteins

A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

Fgf21 compound / glp-1r agonist combinations with optimized activity ratio

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an fgf21 (fibroblast growth factor 21) compound and a glp-1r (glucagon-like peptide-1 receptor) agonist with optimized glp-1r agonist/fgf21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (nash) and/or atherosclerosis..
Sanofi

Pharmaceutical composition for treating a metabolic syndrome

The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Sanofi

Herbo-mineral formulation for prevention, treatment and management of diabetes and preparation thereof

Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating diabetes and diabetes associated complications.
Muniyal Ayurvedic Research Centre

Mannose derivatives useful for treating pathologies associated with adherent e. coli

The mannose derivatives of formulae (i) are useful for treating pathologies associated with the presence of adherent escherichia coli (aec), in particular inflammatory bowel diseases (ibd), such as crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.. .

Pharmaceutical composition of alogliptin and metformin

Present invention relates to a stable pharmaceutical composition comprising intimate mixture of alogliptin and metformin, and suitable pharmaceutically acceptable excipient/s; wherein metformin is present in about 3.3 parts or more parts by weight relative to 100 parts by weight of the total weight of part comprising alogliptin. Invention also encompasses various processes of preparing said pharmaceutical composition and its use in improving glycemic control in adults with type 2 diabetes mellitus..
Torrent Pharmaceuticals Limited

Method of treating hyperglycemia

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type i, ii diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto.
Center Laboratories, Inc.

Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1

Disclosed are methods of treatment of type 1 diabetes (t1d) in subjects under standard-of-care t1d treatment, by administration of substituted long-chain amphipathic dicarboxylic acids. Also disclosed are methods of reducing standard-of-care administered dose of insulin or an insulin analogue and/or obviating the need for administration of insulin or an insulin analogue in a t1d subject by administration of substituted long-chain amphipathic dicarboxylic acids..
Syndromex Ltd.

Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia

Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia are provided herein. Such compositions can contain synergizing amounts of leucine and/or one or more leucine metabolites in combination with nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and with at least one or more anti-diabetic agents.
Nusirt Sciences, Inc.

System and detecting a health condition using an optical sensor

A biosensor includes an optical sensor circuit that emits light directed at skin tissue of a patient at a plurality of wavelengths. A first and second spectral response of light reflected from the tissue is obtained around a first wavelength in a uv range and a second wavelength in an ir range.
Sanmina Corporation

Cell-free methylated and unmethylated dna in diseases resulting from abnormalities in blood glucose levels

Disclosed herein are compositions and methods for determining new-onset type 1 diabetes, methylation-specific polymerase chain reaction assays for determining new-onset type 1 diabetes, methods for distinguishing between type 1 diabetes and type 2 diabetes, methods for dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes and methylation-specific polymerase chain reaction assays for determining dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes.. .
Universite Libre De Bruxelles

Glp-1 and use thereof in compositions for treating metabolic diseases

Compositions and methods for treating type ii diabetes in a subject. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a propeptide and the active portion of glp-1, wherein, when expressed, the n-terminal amino acid of glp-1 immediately follows the c-terminal amino acid of the propeptide.
The Trustees Of The University Of Pennsylvania

Stimulation via tlr4/md-2 to reverse type 1 diabetes

Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati

Production heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystal

Compounds of formula (vi), which are useful as therapeutic drugs for diabetes, may be produced by reacting a compound of formula (ii) with an acid halogenating agent to give an acid halide; reacting the acid halide with a compound of formula (iv) in the presence of a base, and crystallizing compound (v) or a salt thereof from the reaction system; and subjecting the compound of formula (v) to reductive deprotection in the presence of a metal catalyst, and crystallizing the compound of (vi) or a salt thereof from the reaction system:. .
Ea Pharma Co., Ltd.

Heterocyclic compounds for the inhibition of pask

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting pas kinase (pask) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus..
Bioenergenix Llc

Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs

Methods of using fgf1 analogs, such as fgf1 mutant proteins having an n-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant fgf1 proteins can be part of a chimeric protein that includes a β-klotho-binding protein, an fgfr1-binding protein, a β-klotho-binding protein and a fgfr1-binding protein, a c-terminal region from fgf19 or fgf21..
Salk Institute For Biological Studies

Composition and treatment of metabolic disorders

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders.
The Johns Hopkins University

Composition for treating diabetes and dyslipidemia obtained from the extract of costus pictus d.don plant and a preparing the same

The disclosure provides a medicinal composition for treating diabetes and dyslipidemia obtained from the extract of costus pictus d. Don.
Arjuna Natural Extracts, Ltd

Adiponectin secretion enhancer

The present disclosure provides for the administration of β-nmn, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can he ingested in order to increase the secretion of adiponectin.
Oriental Yeast Co., Ltd.

Anti-diabetic effects of gypenoside 75

The present invention relates to a composition for preventing, improving, or treating diabetes mellitus, and more specifically, relates to pharmaceutical, food, and feed compositions comprising gypenoside 75 or a pharmaceutically acceptable salt thereof. Additionally, the present invention relates to a method for preventing or treating diabetes mellitus using the composition..
Intelligent Synthetic Biology Center

Compositions for use in the treatment of diabetes

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof.
University Of Ulster

Therabiome, Llc

. .

Apparatus and methods for taking blood glucose measurements and recommending insulin doses

The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods..
Hygieia, Inc.

Telemonitoring and analysis system

Disclosed is a telemonitoring and analysis system and associated methods. A doctor creates a care plan for a patient with a chronic condition, such as diabetes.
Esvyda!, Inc.

Glycerol-3-phosphate phosphatase activators

The present disclosure relates to the identification and the use of activators of a mammalian glycerol-3-phosphate phosphatase (hg3pp) for increasing gro3p conversion to glycerol and glycerol release from a mammalian cell. The activators of hg3pp can be used in the prevention, treatment and/or alleviation of symptoms associated with obesity, type 2 diabetes and/or metabolic syndrome x.
Val-chum, Limited Partnership

Multi-peptide composition

The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition.
Kings College London

A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.. .
Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et

Algorithms for diabetes exercise therapy

Safe and effective exercise poses a specific set of challenges for subjects diagnosed with diabetes. These challenges include the coordination of exercise with blood glucose monitoring and insulin administration.
Fitscript Llc

Forma Therapeutics, Inc.

. .

Methods and compositions for producing pancreatic beta cells

Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes.
The J. David Gladstone Institutes

Humanized cxcr3 antibodies with depleting activity and methods of use thereof

Provided are humanized cxcr3 antibodies and methods of using the antibodies to treat cxcr3-associated disorders such as type 1 diabetes mellitus (t1d), particularly new-onset t1d, and psoriasis. In certain embodiments, the anti-cxcr3 antibodies are humanized anti-human cxcr3 antibodies with enhanced effector function against cells expressing cxcr3 on their surface.
Sanofi

Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-product

The invention relates to the use of phytate or any of the salts thereof for preventing the formation of advanced glycation end-products (age), toxic products that are produced in pathologies such as diabetes, either alone or combined with b6 vitamins such as pyridoxamine and forming part of a medicament or a pharmaceutical composition produced so as to be administered via oral, rectal, subcutaneous, intra-arterial, intramuscular, intraspinal, intracranial, intravenous or inhalation routes.. .
Servei De Salut De Les Illes Balears ? Ibsalut

5-ht2c receptor agonists and compositions and methods of use

Provided in some embodiments are compounds of formula a, as defined herein, that modulate the activity of 5-ht2c receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea..
Arena Pharmaceuticals, Inc.

Composition for treating diabetes mellitus

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components.

Insulin activity map

An insulin activity map is a tool for assessing a patient's metabolic risk, designing a treatment plan, disseminating the information in a useful way to the patient, and encouraging the patient to remain on a treatment course. The insulin activity map combines a variety of inputs such as insulin sensitivity and insulin production to generate a patient-specific diagnosis and treatment assessment.
Boston Heart Diagnostics Corporation

System, method and kit for analysis of circulating differentially methylated dna as a biomarker of beta-cell loss

β-cell loss in in type 1 diabetes is typically undetected until the development of hyperglycemia, at which point β-cell mass is significantly reduced. Methylation sensitive quantitative real time pcr (qrtpcr) of demethylated circulating free β-cell specific dna can be used as a biomarker of β-cell death.
Nyu Winthrop Hospital

Storage method and banking system of nt cell

Provided are a storage method and a banking system of cells prepared using somatic cell nuclear transfer (nt) technology with homozygous genotypes of genes of human leukocyte antigen (hla)-a, hla-b, hla-dr, and the like. The banking of nt cell-derived stem cells may be applied to autologous or allogenic patients and can provide transplantable cells and tissue materials for the treatment of various diseases such as diabetes, osteoarthritis, parkinson's disease, and the like..
Cha Biotech Co., Ltd.

Crystalline solvate forms of a pharmaceutical

Described herein are solid state 17α-ethynylandrost-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17α-ethynylandrost-5-ene-3β,7β,17β-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.. .
Neurmedix, Inc.

Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

Wherein the groups r, r1, r2, r3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the gpr40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Methods of quantifying n2-(1-carboxyethyl)-2'-deoxy-guanosine (cedg) and synthesis of oligonucleotides containing cedg

Methods of quantifying n2-carboxyethyl-2′-deoxyguanosine (cedg) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring cedg levels before and after treatment.
City Of Hope

Acid containing lipid formulations

The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.. .

Inhibiting ctrp5 action to improve insulin resistance associated with obesity and type 2 diabetes

The presently disclosed subject matter relates to methods of improving insulin sensitivity in cells, tissues, and subjects, as well as methods of reducing insulin resistance, improving glucose homeostasis, reducing hepatic tryglyceride levels, reducing food intake, and treating metabolic disorders, such as those occurring in individuals who are obese, diabetic, and/or have hepatic steatosis.. .
The Johns Hopkins University

Biomarkers related to insulin resistance progression and methods using the same

Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided.
Metabolon, Inc.

Selective modulators of the activity of the gpr55 receptor: chromenopyrazole derivatives

Which have the ability to modulate the receptor of the cannabinoid family gpr55, whereby the invention also relates to the use of these compounds for the manufacture of a medicament for the treatment of diseases in which the gpr55 receptor has a physiological role such as diabetes, parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian and prostate cancer, glioblastoma, and cutaneous carcinoma.. .

Compounds and their use as bace1 inhibitors

The present invention relates to compounds of formula (i) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein x, y, z, q, w, m, u, ring (a), r2, r3, r4, r5 and r6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of formula (i) and a therapeutic method of treating and/or preventing downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, alzheimer's disease, memory loss, attention deficit symptoms associated with alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with parkinson's disease, alzheimer's disease and/or down syndrome, age-related macular degeneration (amd), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, type ii diabetes mellitus and cardiovascular diseases (stroke)..
Allgenesis Biotherapeutics, Inc.

Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer

Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer..
The Uab Research Foundation

System and adjusting insulin delivery

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes.
Bigfoot Biomedical, Inc.

System and adjusting insulin delivery

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes.
Bigfoot Biomedical, Inc.

System and adjusting insulin delivery

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes.
Bigfoot Biomedical, Inc.

System and adjusting insulin delivery

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes.
Bigfoot Biomedical, Inc.

System and adjusting insulin delivery

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes.
Bigfoot Biomedical, Inc.

Vitamin e tocotrienols inhibition of intracellularly obligate pathogen chlamydia and methods of use

This invention reveals the beneficial use of vitamin e tocotrienols for inhibition of chlamydial infections. Chlamydial infection levels in mouse macrophages treated with tocotrienol were decreased >50%, with concomitant aberrant pathogen development.
American River Nutrition, Inc.

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd).. .
Boehringer Ingelheim International Gmbh

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds and the uses of such compounds for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension.. .

Non-invasive occular biomarkers for early diagnosis of diseases

Materials and methods are disclosed for screening advanced glycation end-products from the mammalian ocular lens proteins to quantify early biomarkers for the diagnosis of diabetes mellitus and related complications.. .
Board Of Trustees Of Northern Illinois University

Assays and reagents for diagnosing type 1 diabetes

Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.. .
L2 Diagnostics, Llc

Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof

Provided herein are compounds of formulae (rl), (i), (ii), (iii), (iv), and (v), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity).
President And Fellows Of Harvard College

Tetrahydropyranyl benzamide derivatives

Wherein r, r1-r3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds. .

Lipids that increase insulin sensitivity and methods of using the same

The invention provides, inter alia, fatty acyl hydroxy fatty acid (fahfa; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, metabolic syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate fahfa levels, fahfa-mediated signaling, and fahfa-mediated biological effects.. .
President And Fellows Of Harvard College

Method of delivering subliminal messages

This invention relates to a method of delivering subliminal messages to a user for providing positive benefits by using the subliminal programming app. The frequencies of the subliminal messages are such that which cannot be heard by human ear.

Pharmaceutical composition, methods for treating and uses thereof

The invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Boehringer Ingelheim International Gmbh

Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection..
The University Of British Columbia

Potassium-binding agents for treating hypertension and hyperkalemia

The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.

Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes

In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a gaba receptor agonist, in an amount sufficient to ameliorate said one or more symptoms.
The Regents Of The University Of California

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University

Nano-liposome carrier composition containing hybrid of cas9 protein and guide rna

The present invention relates to nano-liposome carrier compositions that encapsulate a hybrid of a cas9 protein and a guide rna and methods of making and using the same. The nano-liposome carrier compositions have an excellent effect of suppressing expression of target dna, and thus pharmaceutical compositions including the nano-liposome carrier compositions can be used for treating diseases such as diabetes..
Moogene Medi Co. Ltd.

Devices and methods for the treatment of tissue

Systems, methods and devices for the treatment of tissue are disclosed. A system includes an elongate tube with a distal portion.
Fractyl Laboratories Inc.

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services

Treating type i and type ii diabetes

This document provides methods and materials for treating diabetes. For example, methods and materials for using nucleic acid encoding human preproinsulin to treat diabetes (e.g., type i or type ii diabetes) are provided..
Mayo Foundation For Medical Education And Research

Chimeric fibroblast growth factor 19 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Chimeric fibroblast growth factor 21 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf21 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

5-ht2c receptor agonists and compositions and methods of use

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Arena Pharmaceuticals, Inc.

Leukocyte and microparticles fractionation using microfluidics

This invention relates to a method for separating blood cells comprising the steps of: (a) lysing red blood cells of a blood sample and diluting said sample; (b) providing a microfluidic device comprising a spiral-shaped flow channel having at least a first end and a second end, wherein said flow channel has two inlet ports at or near said first end and at least two outlet ports at or near said second end, wherein one of the two inlet ports is located at the inner wall of the spiral-shaped flow channel and the other inlet port is located at the outer wall of the spiral-shaped flow channel and at least one of the outlet ports is connected to a container allowing the storage of blood cells; (c) introducing the sample of step (a) into the inlet port located at the outer wall of the spiral-shaped flow channel and introducing a sheath fluid into the inlet port located at the inner wall of the spiral-shaped flow channel; (d) driving said sample and the sheath fluid through the spiral-shaped flow channel; and (e) recovering the blood cell in the at least one container connected to the at least one outlet port. The present invention also relates to coupling above described method of purifying neutrophils in the native state with a method for diagnosing diabetes or an inflammatory disease in a subject, which involves further investigation of neutrophils by determining their rolling speed, the neutrophil circularity (nc) index and/or the expression of markers, such as intracellular reactive oxygen species (ros), cd1 1 b or psgl-1..
Nanyang Technological University

Method of treating diabetes type 2 by administering ultrarapid acting insulin

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.. .
Mannkind Corporation

Exendin-4 derivatives as dual glp1/glucagon agonists

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Synthetic composition for microbiota modulation

A human milk oligosaccharide (hmo) or a synthetic composition comprising said hmo, for use in increasing the abundance, particularly the relative abundance, of a bifidobacterium of the b. Adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human.
Glycom A/s

Compositions and methods for diagnosis and treatment of inflammation

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.. .
The United States Of America As Represented By The Secretary Of The Navy

Compositions and methods for treating neurological diseases or injury

Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin k are provided..
Musc Foundation For Research Development

High-purity galactooligosaccharide compositions, preparations, and applications thereof

Provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, kluyveromyces lactis atcc 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides.
King-prebiotics Biotechnology (tw) Co., Ltd.

High-purity galactooligosaccharide compositions, preparations, and applications thereof

Provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, kluyveromyces lactis atcc 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides.
King-prebiotics Biotechnology (tw) Co., Ltd.

Method for controlling differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating sirt1 expression

The present disclosure relates to a method for controlling the differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating sirt1 (silent mating type information regulation 2 homolog; sirtuin 1) expression, the method, which controls the differentiation of embryonic stem cells into adipocytes by regulating sirt1 expression, being capable of controlling the inhibition or promotion of adipocyte differentiation in accordance with the timing of a sirt1 expression inhibitor treatment. Furthermore, kidney precursor cell differentiation can be regulated by a sirt1 expression inhibitor or promoter treatment.
Chonbuk National University Hospital

Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose tolerance

Described are molecules specifically binding to human islet amyloid polypeptide (hiapp) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (iapp) induced β-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (t2d).. .
University Of Zurich

Nanoparticle-based antigen specific immunotherapy

The present invention provides a nano particle comprising: a core comprising metal atoms; a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprises: at least one carbohydrate ligand; at least one glutathione ligand; and at least one autoantigen peptide ligand. Also provided are compositions and vaccines comprising the nanoparticles, methods for producing the nanoparticles and medical uses of the nanoparticles, including for antigen specific imunotherapy of an autoimmune disease, such as diabetes mellitus type 1, in a mammalian subject..
Institut National De La Sante Et De La Recherche Medicale

Fusion proteins

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human igg fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time..
Eli Lilly And Company

Bifidobacteria as probiotic foundation species of gut microbiota

This invention relates to novel probiotic bifidobacteria strains, particularly, a b. Pseudocatenulatum strain, and its use as probiotic, and food products, feed products, dietary supplements and pharmaceutical formulations containing them.
Perfect (china) Co., Ltd.

Glucoraphnin for use in the treatment and/or prevention of diabetes mellitus

A composition comprising glucoraphanin for use in: reducing fasting serum glucose levels in a subject administered with said composition when compared to a subject not administered said composition; and/or preventing diabetes mellitus and/or a condition associated therewith, treating diabetes mellitus and/or a condition associated therewith, or a combination thereof in a subject; wherein the composition is intermittently administered to the subject between about 1 to about 5 times per week such that said subject is administered with a weekly dose of between about 300 to about 2500 μmoles of glucoraphanin, as well as uses of a composition prepared from a high glucosinolate broccoli and/or methods of: reducing fasting serum glucose levels in a subject having elevated fasting serum glucose levels; preventing diabetes mellitus and/or a condition associated therewith in a subject; treating a subject having diabetes mellitus and/or a condition associated therewith; or combinations thereof.. .
Plant Bioscience Limited

Diagnostic target

A method for the diagnosis of type 1 diabetes, or a predisposition towards type 1 diabetes, or to monitor the efficacy of a therapy to prevent or treat type 1 diabetes, said method comprising contacting a sample from a subject with a reagent selected from tetraspanin-7 or a fragment, or a modified form thereof, and detecting an interaction indicative of the presence of an autoimmune response to tetraspanin-7. Tetraspanin-7 is now understood to be the protein recognised by glima 38 specific antibodies.
The University Of Lincoln

Antibodies that recognize iapp

The invention provides monoclonal antibody 6b8 and related antibodies. The 6b8 antibody binds to an epitope within residues 3-12 of iapp.
Prothena Biosciences Limited

Bicyclic heteroaryl derivatives as cftr potentiators

The present invention relates to 1,3-disubstituted-1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of cystic fibrosis transmembrane conductance regulator (cftr).
Cystic Fibrosis Foundation Therapeutics, Inc.

Human glut5 specific inhibitors and methods of treatment

The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human glut5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of glut5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through glut5, including such disease states and conditions as glut5 deficiency syndrome, diabetes (type i and ii), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others..
Rosalind Franklin University

Insulin containing pharmaceutical compositions

The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy..
Novo Nordisk A/s

Beta-casein a2 and antioxidant capacity

Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta-casein to the animal for consumption, where the beta-casein comprises at least 75% by weight of one or more beta-caseins not capable of producing beta-casomorphin-7 on enzymatic digestion. Uses include as an oxidant, for treating or preventing the symptoms of cancer, inflammation, kwashiorkor (protein deficiency), seizure, autism, down's syndrome, chronic fatigue syndrome, alzheimer's disease, parkinson's disease, sickle cell anaemia, liver disease, cystic fibrosis, hiv, aids, infection, heart attack, stroke, and diabetes, avoiding or reducing the effects of aging, promoting the recovery of tissue following physical exercise, and promoting fertility..
The A2 Milk Company Limited

Inhibitor of igfbp3/tmem219 axis and diabetes

The present invention relates to the role of the igfbp3/tmem219 axis in the onset of diabetes and the related use of igfbp3/tmem219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing type 1 and/or type 2 diabetes and relative kit..
Ospedale San Raffaele Srl

Fgf receptor ligands for treating diabetes and obesity

Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system fgf receptor homodimer.. .
Albert Einstein College Of Medicine, Inc.

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. .
Boehringer Ingelheim International Gmbh

Triazine derivatives as interferon-gamma inhibitors

The present invention relates to interferon-gamma (ifn-γ) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of ifn-γ production, such as alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, sjögren's syndrome, crohn's disease, and type 1 diabetes mellitus. The compounds are of formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof..
University Of Greenwich

Use of a statin compound as local drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Small molecule analogs of the nemo binding peptide

The invention is directed to a method of inhibiting, within a living cell, the interaction between nf-κb essential modulator (“nemo”) with iκb kinase-β (ikk-β) at the nemo binding domain (nbd), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a nemo-binding domain analog (nbda). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between nf-κb essential modulator (“nemo”) with iκb kinase-β (ikk-β) at the nemo binding domain (nbd) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention.
The Scripps Research Institute

Antidiabetic oral insulin biguanide combination

Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes. Also disclosed are methods for achieving improved glucose tolerance and glycemic control in a diabetic mammal without any statistically significant increase in weight, risk of hypoglycemia or hyperinsulinemia, and the need for monitoring blood glucose concentrations or hba1c levels, and methods for reducing the incidence and/or severity of one or more disease states associated with chronic dosing of insulin; for prophylactically sparing (3-cell function or for preventing (3-cell death or dysfunction in a mammal with impaired glucose tolerance or early stage diabetes mellitus; and for long-term protection from developing (or delaying the onset of) overt or insulin dependent diabetes in a mammal with impaired glucose tolerance or early stage diabetes..
Emisphere Technologies, Inc.

Substance p, mast cell degranulation inhibitors, and peripheral neuropathy

Described herein are methods of using substance p, mast cell degranulation inhibitors, or combinations thereof to delay the onset of, to reverse, or to reduce the risk of acquiring complications associated with diabetes. Also provided herein are methods for accelerating wound healing in diabetic subjects using substance p, mast cell degranulation inhibitors, or combinations thereof..
Beth Israel Deaconess Medical Center, Inc.

Use of factor xa inhibitors for regulating glycemia

The present invention concerns a factor xa inhibitor for use as a medicament in a method for regulating glycemia in a subject, in particular for use for preventing and/or treating hyperglycemia, impaired glucose tolerance, impaired fasting glucose, insulin resistance and/or diabetes.. .
Vaiomer

Synthetic triterpenoids and methods of use in the treatment of disease

The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.. .
Trustees Of Dartmouth College

Methods and devices for determining metabolic states

In vivo or in vitro sensors in combination with an electronic monitor enable the recognition, quantitation, and tracking of metabolic oscillations of living cells immobilized on or in close proximity to an analyte sensor providing methods, systems, and devices to monitor, probe, diagnose or treat abnormal metabolic states. The patterns or fingerprints of metabolic oscillations yield information about analyte concentration and the status of cellular metabolism.
Ultradian Diagnostics Llc

Multiple-marker risk parameters predictive of conversion to diabetes

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (str) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (fpg) values.
Liposcience, Inc.

System and determining risk of diabetes based on biochemical marker analysis

A method for predicting risk of gestational diabetes mellitus (gdm) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of pai-2 and stnfr1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing gdm.. .
Wallac Oy

Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells

Compositions and methods are provided for generating islet-like cell clusters. The methods include culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having bone morphogenetic protein (bmp) activity (e.g., a bmp polypeptide).
University Of Miami

Compounds as peptidic glp1/glucagon/gip receptor agonists

The present invention relates to trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Compounds as peptidic trigonal glp1/glucagon/gip receptor agonists

The present invention relates to trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Ertugliflozin co-crystals and process for their preparation

The present invention relates to processes for the preparation of an ertugliflozin-l-pyroglutamic acid (1:1) and co-crystal ertugliflozin-l-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-l-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus..
Sun Pharmaceutical Industries Limited

Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol

The present invention is directed to an anhydrous crystalline for of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol, pharmaceutical compositions containing said anhydrous crystalline form and its use in the treatment glucose-related disorders such as type 2 diabetes mellitus and syndrome x.. .
Janssen Pharmaceutica Nv

2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1

The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of formula (i) and new 2-oxo-1,2-dihydropyridine-3-carboxamide compounds of formula (ii) in the treatment of pathologies which require an inhibitor of pdk1 enzyme such as diabetes, neurodegenerative diseases such as alzheimer's and prion diseases, and tumours such as breast, and pancreatic cancers and glioblastoma, particularly glioblastoma.. .
International Society For Drug Development S.r.l.

System for monitoring safety in medication delivery for diabetes management

An integrated diabetes management (idm) system includes a safety layer which, in one configuration has two components, one located between a glucose sensor and a controller and a second component located between a controller and a pump, to monitor various aspects of signals and modify those signals for compatibility and safety purposes. In one application, the safety layer receives output control signals from a controller and modifies those control signals as a function of an actual amount of insulin delivered to the user.
Abbott Diabetes Care Inc.

Composition and uses thereof

The invention relates to compositions comprising pinus pinaster stem bark extract, papain, and aloe vera extract, and methods of manufacturing same. There are also described methods of treating or preventing a variety of conditions, including treating or preventing elevated blood glucose, pre-diabetes, type 2 diabetes, autoimmune diseases, reducing or decreasing inflammation, treating or preventing diseases characterised by elevated levels of inflammation, and lowering blood cholesterol, said methods comprising administering an effective amount of a composition according to the invention to a subject in need thereof.
Arborvitae Health And Wellbeing Pty. Ltd.

Therapies for obesity, diabetes and related indications

The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.. .
Palatin Technologies, Inc.

Methods for treating overweight or obesity

The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 ml of water per gram of crosslinked carboxymethylcellulose.
Gelesis, Llc

Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Pharmaceuticals compositions comprising the 2s, 4r, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2r, 4s ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, metabolic syndrome, and other diseases and conditions, including but not limited to cushing's syndrome, depression, and glaucoma.. .
Cortendo Ab (publ)

Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria

Provided is a composition containing lactobacillus reuteri elf corresponding to a novel lactic acid bacteria strain and 5-aminolevulinic acid. The composition may be significantly effective to prevent and treat degenerative brain disease and have excellent anti-obesity and anti-diabetes effects, such that the present invention may provide various pharmaceutical composition, health foods, and the like, using the same..
Wedea Inc.

Method of epigenetic analysis for determining clinical genetic risk

The present invention provides a method for identifying a subject having or at risk of having a metabolic disease, such as diabetes or obesity. The invention is based on an approach to identify candidate genes involved in metabolic diseases, such as obesity and type 2 diabetes (t2d) through epigenetic mechanisms.
The Johns Hopkins University

Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

Wherein the groups r, r1, r2, r3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the gpr40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes.

Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators

A method of identifying compounds as direct inhibitors of keap1-nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of keap1-nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, alzheimer's, and parkinson's.
The Broad Institute, Inc.

Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject.
Animas Llc

Apparatus and system for diabetes management

An apparatus and system diabetes management. The apparatus comprises a body which houses: (i) at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; (ii) a processor operatively connected to the at least first memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen; (iii) a display screen operatively connected to the processor, (iv) a quantity of insulin; (v) a needle communicating with the quantity of insulin for delivering insulin to the patient; (vi) means for effecting delivery of a portion of the quantity of insulin to the patient via the needle; and (vii) metering means for controlling the portion of the quantity of insulin delivered to the patient via the needle..
Hygieia, Inc.

System and methods for improved diabetes data management and use employing wireless connectivity between patients and healthcare providers and repository of diabetes management information

Methods, devices and a system for disease management are provided that employ diagnostic testing devices (e.g., blood glucose meters) and medication delivery devices (e.g., insulin delivery devices) for providing data to a repository in real-time and automatically. Repository data can be analyzed to determine such information as actual test strip use, patient health parameters to outside prescribed ranges, testing and medication delivery compliance, patient profiles or stakeholders to receive promotional items or incentives, and so on.
Becton, Dickinson And Company

Non-obese diabetes mice and its applications

The invention relates to a novel non-obese diabetic (nod) mouse and its application. Particularly, the invention relates to a nod mouse specifically expressing anti-polyethylene glycol membrane antibody reporter (anti-peg reporter) in the nod mouse..
Taipei Medical University

Pancreatic stromal progenitor cells

This disclosure relates to pancreatic stromal progenitor cells. This disclosure also relates to isolation of pancreatic stromal progenitor cells.
Alfred E. Mann Institute For Biomedical Engineer- Ing At The University Of Southern California

Acylated glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Zealand Pharma A/s

Pyrrolopyrimidines as cftr potentiators

Wherein r1a, r1b, r2, r3, r4, w, y, and z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of cystic fibrosis transmembrane conductance regulator (cftr).

Therapeutic compounds

The invention provides compounds and compositions that are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.. .
Arizona Board Of Regents On Behalf Of Arizona State University

Compositions, kits and methods for treating type ii diabetes mellitus

Disclosed herein are methods for treating type ii diabetes mellitus. In particular, the present invention relates to methods of using an extract of hedychium coronarium koenig and a blood glucose reduction agent, to synergistically reduce the blood glucose level of the subject having type ii diabetes mellitus..
Vitnovo, Inc.

Method of treating focal segmental glomerulosclerosis

A method of treating focal segmental glomerulosclerosis with a compound of formula i is provided. Fsgs may be primary (no known cause) or secondary.
Chemocentryx, Inc.

Metabolically programmed metal chelators and uses thereof

The present invention provides compounds of formula (i), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of formula (ii), which are also “metabolically programmed” metal chelators.
University Of Florida Research Foundation, Incorporated

Skin barrier repair and maintenance composition

A composition of matter and method for treating compromised skin is disclosed, providing improved skin barrier repair and maintenance properties. The composition of matter comprises at least one lipid selected from a group consisting of lipids defined by a predetermined lipid profile and at least one skin nutrient selected from a group consisting of nutrients defined by a predetermined nutrient profile, but is substantially free of petrolatum.
Skinintegra, Inc.

Location-based wireless diabetes management systems, methods and apparatus

Embodiments provide systems, methods and apparatus for diabetes management using location-based reminders. Embodiments include requesting a user select a diabetes management related task to be reminded to perform; requesting the user select a location at which the user is to be reminded to perform the selected diabetes management related task; monitoring the user's location; detecting the user has entered the selected location; triggering the reminder in response to detecting the user has entered the selected location; and presenting the reminder to the user.
Ascensia Diabetes Care Holdings Ag

System for improving diabetes testing and reducing counterfeiting

A diabetes test system for measuring blood glucose levels is provided, which includes a glucose meter, at least one diabetic test strip, and a container or pouch for storing the diabetes test strips and protecting them during transport. Methods of packaging diabetes test strips are also provided.

Methods for treating diabetes

Methods for treating diabetes by administering an inhibitor of gdf-8, or a related member of transforming growth factor-beta (tgf-β) superfamily of structurally-related growth factors (e.g., gdf-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as glut4 and glut 1, in a subject by administering an inhibitor of gdf-8.
Scidera, Inc.

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Ethynyl derivatives

The present invention relates to positive allosteric modulators (pams) of metabotropic glutamate receptor 4 (mglur4) that may be used for the treatment of conditions such as parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

The present invention provides a composition comprising a therapeutically effective amount of a polypeptide, peptide, or analog corresponding to one or more of seq id no(s) 1, 2, 3 or 4, and or more of a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, and/or pharmaceutically acceptable excipient. The polypeptide therapeutic of the present invention may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation.
Imagine Pharma

Enrichment methods for preparing tannic acid compositions

Methods for preparing tannic acid-containing compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions), particularly those having enriched tannic acid populations with superior potency, purity and safety profile. Also provide herein are the tannic acid-containing compositions for use in inhibiting d-amino acid oxidase and/or for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia..
Syneurx International (taiwan) Corp.

Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion

Compositions comprising monoacylglycerols (mag), such as sn-1(3) mag, and further comprising fat-soluble nutrients such as fat-soluble vitamins and carotenoids, are administered to an individual having or at risk of a nutrient deficiency induced by maldigestion, such as maldigestion associated with chronic pancreatitis, cystic fibrosis, diabetes, pancreatic duct obstruction, a pancreatic tumor, or shwachman-diamondsyndrome (sds). The compositions and the methods of using the compositions enhance absorption of fatty acids and the fat-soluble nutrients to address nutritional deficiencies due to maldigestion..
Nestec S.a.

Blood glucose management device for calculating bolus insulin

A method of operating a glucose management device. The glucose management device includes one or more processing components, a housing, a user interface including a display and a user-input mechanism, and a memory.
Ascensia Diabetes Care Holdings Ag

A predicting the risk of incidence of chronic kidney diseases

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh

Method for the prognosis and/or diagnosis of an illness based on a sample of adipose tissue, and a kit for said method

The invention relates to a method for the prognosis of adiposity and the prognosis and/or diagnosis of a disease selected from the group consisting of diabetes, cardiovascular diseases and metabolic syndrome.. .
Lipozyt Marker Ug

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Z4, z7, z9, z11, z22, z23, z26, z30, z34, z35, p, m, n, q, and bridge are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof.

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β,25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

Epoxyazulene derivatives useful for treating cancer and diabetes

Disclosed is a compound of formula (i) in which r1-r5 and x1 are as described herein. Also provided are methods of using a compound of formula (i), including a method of treating cancer and a method of treating diabetes..
Universitat Rovira I Virgili

Ethynyl derivatives

The compounds may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .

Eckol derivatives, methods of synthesis and uses thereof

Provided herein are eckol derivatives, methods of synthesis thereof and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, alzheimer's disease, microbial infections, obesity, diabetes, cancer or inflammation using the compounds and pharmaceutical compositions disclosed herein..
Phloronol, Inc.

Novel compounds for treating diabetes

The present invention provides a class of novel aryl pseudo-c-glycoside compounds that are effective for treating diabetes. Also provided are methods for making such compounds and methods for treating diabetes by administering such compounds to patients who have been diagnosed with diabetes or are at risk of developing diabetes..
The Chinese University Of Hong Kong

Treating diabetes melitus using insulin injections administered with varying injection intervals

The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.. .
Novo Nordisk A/s

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Probiotic compositions for improving metabolism and immunity

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera ileibacterium and dubosiella, including their species i.
New York University

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Methods and formulations for modulating lyn kinase activity and treating related disorders

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..
Melior Pharmaceuticals I, Inc.

Nitrated-fatty acids modulation of type ii diabetes

Nitro oleic acid and related metabolites are agonists of ppar-γ. Surprisingly, nitro oleic acid is a more potent agonist of ppar-γ, relative to nitro linoleic acid.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gb s), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.

Gdanski Uniwersytet Medyczny

. .

Diabetes management therapy advisor

A method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose.
Aseko, Inc.

Compositions and methods for diagnosing and treating autoimmune diseases

Disclosed are compositions and methods for detecting, isolating, and/or characterizing a t cell or autoantibody associated with type i diabetes. The composition and methods comprise the use of a hybrid insulin peptide having an n-terminal amino acid sequence taken from the human insulin peptide and a c-terminal amino acid sequence taken from a secretory granule protein that are joined through a peptide bond to form an autoimmune antigen.
The Regents Of The University Of Colorado, A Body Corporate

Melanocortin receptor ligands modified with hydantoin

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .
Ipsen Pharma S.a.s.

Peptide with anti-obesity and anti-diabetes activity and use thereof

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of pparγ, acc, and ap2, which are adipogenic markers, increase the expression of phsl, ampk-α1, cgi-58, and atgl, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values.
Caregen Co., Ltd.

Sk and ik channel agonists for treatment of heart failure

The present invention provides compounds that are improved potassium channel agonists. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided.
The Trustees Of Columbia University In The City Of New York

System for managing glucose levels in patients with diabetes or hyperglycemia

A blood glucose maintenance system for use by hyperglycemic individuals measures their blood glucose level and calculates an appropriate glucose or insulin dosage based on the measurement. Recheck intervals responsive to dosage history are determined.
Indiana University Health, Inc.

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
The Methodist Hospital

Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1

Treg cells cd3(+)cd4(+)cd25(high)cd127(−). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying treg cells in vitro..

Tolerogenic dna vaccine

The present invention relates to plasmids useful for prevention and/or delay of e.g. Type 1 diabetes..
Novo Nordisk A/s

Insulin mimotopes and methods of using the same

Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive t cells into foxp3+ regulatory t cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes..
National Jewish Health

Pharmaceutical compositions for combination therapy

The present application relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a fxr mediated disease or condition, such as nafld and nash, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity..
Intercept Pharmaceuticals, Inc.

Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Deuterx, Llc

Modulators of farnesoid x receptor and methods for the use thereof

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.. .
Xiamen University

Methods of preventing and treating autoimmunity

Methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided..
The University Of Florida Research Foundation Incorporated

Computer-based diabetes management

A computer-based method includes receiving, from a computer-based user interface, user-specified information about one or more events influential on the user's blood glucose level, generating, with a computer-based processor, a plurality of estimated trajectories of the user's blood glucose level as influenced by the one or more events, receiving a set of data that represents actual blood glucose measurements for the user, and identifying, with the computer-based processor, which of the estimated trajectories represents a best fit to the set of data that represents the actual blood glucose measurements for the user. At least some of the actual blood glucose measurements occurred later in time than a start time of the one or more events influential on the user's blood glucose level.
Bigfoot Biomedical, Inc

Neural stem cell therapy for obesity and diabetes

Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) iκb kinase (ikkβ) activation of nuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb) or (ii) notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity’..
Albert Einstein College Of Medicine, Inc.

Analogs of glucagon exhibiting gip receptor activity

Provided herein are glucagon analogs which exhibit potent activity at the gip receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an ec50 at the gip receptor which is within the nanomolar or picomolar range..
Hoffmann-la Roche Inc.

Peptide analogs for treating diseases and disorders

Provided herein are methods for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences seq id no: 12, seq id no: 15 and seq id no: 17 are administered..
Keybioscience Ag

Novel cyclosporin derivatives and uses thereof

Or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.. .

Methods and compositions for inhibiting the interaction of menin with mll proteins

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of mll1, mll2, mll fusion proteins, and/or menin..
The Regents Of The University Of Michigan

Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject.
Lifescan, Inc.

Method and pharmaceutical composition for use in the treatment of diabetes

The present invention relates to an apj receptor agonist for use in the treatment or the prevention of diabetes.. .
Centre Hospitalier Universitaire De Toulouse

Zanthoxylum myriacanthum var. pubescens essential oil and application thereof in preparation of drug for treating diabetes

The invention relates to a pneumatic brake release apparatus used on an elevator traction machine. By means of the technical solution, the air films in the air cabin are pushed by using compressed air to drive the push rod to transfer a thrust force, so that the locking arms are unfolded, and the locking brake and the brake release are implemented in a pneumatic way.
Affiliated Xishuangbanna Tropical Botanical Garden Chines

Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sglt2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a sglt2 inhibitor is administered to the patient.
Boehringer Ingelheim International Gmbh

Protein restriction for diabetes

Treating a subject with at least one of diabetes, hyperinsulinemia, or glucose intolerance, can include: during a first low-protein time period of at least 4 consecutive days, administering nutrient material to the subject such that the subject has a bodily intake of protein of less than 20 grams per day and a bodily intake of carbohydrate of at least 40 percent of the subject's bodily intake of energy; and during a first normal-protein time period of at least 4 consecutive days that is after the low-protein period, administering to the subject a normal daily bodily intake of protein of at least 40 grams.. .

Btg International Limited

. .

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. .
Glaxosmithkline Intellectual Property Development Limited

Diabetes treatment

Methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy..
Beth Israel Deaconess Medical Center

Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
Volant Holdings Gmbh

Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes

The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (snp) selected from the group consisting of: slc16a11—rs75493593; hnf1a—rs483353044; tcf7l2—rs7903146; cdkn2a/b—rs10811661; cdkal1—rs7756992; slc30a8—rs3802177; igf2bp2—rs4402960; fto—rs9936385; pparg—rs1801282; hhex/ide—rs1111875; adcy5—rs11717195; jazf1—rs849135; wsf1—rs4458523; ins—igf2—rs149483638; kcnq1—rs2237897; and kcnj11—rs5219, and/or an snp in linkage disequilibrium with any one of said snps at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention..
Patia Biopharmia, S.a. De C.v.

Acylated glucagon analogue

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Boehringer Ingelheim International Gmbh

Dipeptidyl peptidase-iv (dppiv), inhibitory peptide compound, composition containing the same, and production the same

A peptide compound having a dipeptidyl peptidase-iv (dppiv) inhibitory activity or a composition containing the peptide compound that can make a contribution to the prevention of the onset of pathology or the progression in diabetes mellitus patients or those at risk of diabetes mellitus can be provided according to the present invention by a simple method using, as a raw material, milt of a fishery product, which has been eaten for ages and has high safety. In the present invention, a peptide compound having a peptidyl peptidase-iv (dppiv) inhibitory activity obtained in a hydrolysate of a milt protein source obtained from a fishery product is used as an active component of a composition for inhibiting dppiv..
Maruha Nichiro Corporation

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof.

Compositions and methods for treatment of insulin-dependent diabetes mellitus

This invention provides methods of treating insulin-dependent diabetes mellitus in a subject comprising administering to the subject a self-vector encoding human proinsulin. The invention also provides a pharmaceutical composition comprising a self-vector encoding human proinsulin, as well as treatment and maintenance regimens for administering the pharmaceutical composition to a subject..
Bayhill Therapeutics, Inc.

Treatment type 2 diabetes mellitus patients

A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.. .
Sanofi-aventis Deutschland Gmbh

Use of human small leucine zipper protein in adipocyte differentiation procedure

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, slzip binds with pparγ2 to induce the formation of a complex of hdac3 and pparγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of pparγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor..
Korea University Research And Business Foundation

Compositions containing tannic acids and uses thereof

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are d-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.. .
Syneurx International (taiwan) Corp.

Novel methods of use of tetrahydroberberine (thb)

Tetrahydroberberine (thb), isolated from the chinese herb “corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (thb), thb analogs or derivatives, tetrahydroprotoberberines (thpb).
Dignity Health

Treating or preventing nephrogenic diabetes insipidus

In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a ampk activator to a subject in need thereof, wherein in certain embodiments, the ampk activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus..
Emory University

Capsules with intracapsular microspheres for improved survival and function of encapsulated cells

Provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at least one cell. The improved survival and/or function of the at least one live cell in the microcapsule is compared to a live cell in a microcapsule in the absence of the compound capable of improving survival of the at least one cell.
The Board Of Trustees Of The University Of Illinois

Anti-cxcr3 antibodies and methods of use thereof

The present disclosure provides anti-cxcr3 antibodies and methods of using the antibodies to diagnose and/or treat cxcr3-associated disorders such as diabetes mellitus type i (t1d), particularly new-onset t1d. In certain embodiments, disclosed herein are cxcr3 neutralizing antibodies..
Genzyme Corporation

Substituted 3-haloallylamine inhibitors of ssao and uses thereof

The invention also relates to methods of using compounds of formula i, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.. .

Use of long-acting glp-1 peptides

The invention relates to use of long-acting glp-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.. .
Novo Nordisk A/s

Use of tetraspanin-2 for treating diabetes and screening an anti-diabetic agent

There is provided a method for treating diabetes, the method comprising administering to a subject in need thereof an effective amount of a tetraspanin-2 (tspan2) protein expression or activity inhibitor. Further, there is provided a method for screening a diabetes therapeutic agent, the method comprising: (a) bringing a test material into contact with a cell expressing tspan2 gene; (b) determining the expression level of the tspan2 gene in the cell of (a) and in a control cell which is not in contact with the test material; and (c) selecting, as a diabetes therapeutic agent candidate, the test material reducing the expression level of the tspan2 gene in comparison with the control cell..
Korea Basic Science Institute

Methods for treating ocular diseases

The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of formula a1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (pvr), uveitis, glaucoma and age related macular degeneration (amd), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (dr) and diabetic macular edema (dme).. .
Springsky Biomed Company Limited

Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers

The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of sab protein or the rna encoding sab protein relative to a control sample.
The Florida International University Board Of Trustees

Method for decreasing the body fat content in a subject by administering an actriib protein

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.. .
Acceleron Pharma Inc.

Growth differentiation factor 15 (gdf-15) constructs

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

. .

Treatment of diabetes using agonists of the mas-related gpcr d

Methods of identifying agonists of mrgd for treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders. Methods of treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders comprising administering to a subject an agonist of mrgd..

Heteroaryl compounds and methods of use thereof

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Therapeutic compounds

The invention provides compounds formula (i) and salts thereof: wherein the bond represented by ---- is a single bond or a double bond, and r1 has any of the values defined in the specification. The compounds are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia..
Arizona Board Of Regents On Behalf Of Arizona State University

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (i) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Inhibitors of histone deacetylase

Or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein x1, x2, x3, x4, x5, w1, w2, w3, and w4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them.

Tolerogenic nanoparticles for treating diabetes mellitus

Methods and compositions for increasing the number and/or activity of regulatory t cells (tregs) in vivo and in vitro, to induce tolerance to diabetogenic autoantigens.. .
The Brigham And Women`s Hospital, Inc.

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation..
Boehringer Ingelheim International Gmbh

Composition and preparation and uses thereof for preventing and treating diabetes

Disclosed is a composition for use in the prevention, treatment, and management of diabetes in human and animal subjects that contains 2,3,5,4-tetrahydroxystilbene 2-o-b-glucopyranoside collected from one or more plants selected from the group consisting of fallopia genera of plants.. .

Carbazole-containing sulfonamides as cryptochrome modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula i wherein the variable r1, r2, r3, r4, r5, r6, r7, a, b, c′, d, e, f, g, h′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula i to treat a cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, cushing's syndrome, and glaucoma..
Reset Therapeutics, Inc.

Methods and compositions for treating degenerative and ischemic disorders

Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (oxphos) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism.
The General Hospital Corporation

Amelioration of neural deficits associated with diabetes

Methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.. .
Neuralstem, Inc.

Tesofensine, beta blocker combination formulation

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder..
Saniona A/s

Antibodies against modified insulin for use in treatment of and assays for diabetes

The present invention provides a method of diagnosing type 1 diabetes (t1d) or latent autoimmune diabetes in adults (lada) in a subject comprising testing a sample from the subject for the presence or absence of antibodies against modified insulin, wherein the presence of antibodies against modified insulin in the sample is indicative of t1d or lada in the subject. The invention also provides a method of treating t1d or lada in a subject in need thereof.
Queen Mary University Of London

Identification of bitter ligands that specifically activate human t2r receptors and related assays for identifying human bitter taste modulators

The present invention relates to the discovery that specific human taste receptors in the t2r taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific ht2r9 alleles and their disparate activity in functional assays with the same biter ligands.
Senomyx, Inc.

Antibodies and methods for wnt pathway-related diseases

The transmembrane e3 ubiquitin ligases znrf3 and rnf43 are negative regulators of β-catenin and the wnt signaling pathway in eukaryotic cells. The activity of znrf3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in wnt signaling.
Novartis Ag

Indazole derivatives useful as glucagon receptor antagonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Therapeutic compounds

The invention provides compounds formula (i) and salts thereof: wherein r1-r4 have any of the values defined in the specification. The compounds are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia.
Arizona Board Of Regents On Behalf Of Arizona State University

Indazole derivatives useful as glucagon receptor antagonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Tesofensine compositions

The present invention relates to tesofensine compositions, methods to prepare the same and uses thereof in preparing medicines for the prevention and treatment of overweight, obesity and type 2 diabetes mellitus.. .
Saniona A/s

Indole derivatives useful as glucagon receptor antagonists

The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Agents useful for treating obesity, diabetes and related disorders

This invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and df-1176-178.. .
The Regents Of The University Of California

Novel marker for gestational diabetes

The present invention relates to methods of typing a female subject as being at risk of developing gestational diabetes, comprising determining a level of expression of secreted frizzled-related protein 4 (sfrp4). The invention further relates to methods of treating of a subject being at risk of developing, gestational diabetes, comprising typing the subject according to the methods of the invention, and treating the subject with a dietary meal plan and/or physical activity.
Iq Products B.v.

Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes

Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from type i diabetes.
University Of Florida Research Foundation, Inc.

Insulin analogues with a glucose-regulated conformational switch

A two-chain insulin analogue contains an a chain modified by (i) a monomeric glucose-binding element at or near its n terminus and (ii) a b chain modified by at or near its c terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated).
Case Western Reserve University

Traditional chinese medicine composition for preventing and treating externally diabetes and a using the same

The invention discloses a traditional chinese medicine composition and a method thereof for preventing and treating externally diabetes, which is characterized in that the traditional chinese medicine composition is composed of astragalus membranaceus, salvia miltiorrhiza, stigma maydis, cortex lycii radicis, wolfberry, prunella vulgaris, mulberry leaf, cornus officinalis, lycopodium clavatum, the root of bidentate achyranthes, rhizoma chuanxiong, chinese atractylodes, yam, puerarin, fructus arctii, cassia twig; the method of use is to put a 40-50 g/ml medicine bags of the chinese herbal medicine powder or decoction into a foot pot, brew with boiling water, and then steam more than 10 minutes with the traditional chinese medicine steam after stirring evenly. When the water is cooled to 40-42° c., soaking feet once a day before going to bed, a course for foot soaking being 20 days; the contents of blood glucose and symptom of polydipsia, polyuria and polyphagia of the patients can be effectively reduced and disappeared by the foot bath in traditional chinese medicine, thus improving the immunity of the body and activating the autoimmunity as well as promoting the self-healing ability for the disease; and also such diseases as diabetic peripheral neuropathy (dpn), diabetic foot, diabetic nephropathy (dn), uremia caused by renal insufficiency resulted from diabetes can be prevented..

Compositions and methods for increasing lifespan and health span

Disclosed herein are compounds, extracts, and active fractions of the plant geum japonicum and methods for increasing longevity and survival potency or for preventing or treating various medical conditions, including diabetes, inflammation, wound healing, bed sores, and ocular disorders. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods.
Generex Pharmaceuticals, Inc.

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Provided herein are therapies, and methods using that therapy, in the treatment of one or more of type 2 diabetes (t2d), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population..
The University Of British Columbia

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity

The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of gpr30/gper for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ros)..
Stc. Unm

Methods of preventing progression to type 2 diabetes mellitus

The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.. .
Vivus, Inc.

Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation

Activation of 5-ht2a receptors using agonists at surprisingly low concentrations was shown to potently inhibit tnf-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (r)-doi, even many hours after treatment with tnf-α.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Method, system and computer readable medium for predictive hypoglycemia detection for mild to moderate exercise

A system, method and non-transient computer readable medium for predicting hypoglycemic risk in patients with diabetes following moderate exercise. A system may include a digital processor; and an exercise module configured to generate a hypoglycemia risk signal with a hypoglycemia prediction algorithm and to determine a hypoglycemia risk state with a classifier algorithm that classifies the hypoglycemia risk signal to identify an actionable hypoglycemia risk state based on a predefined threshold..
University Of Virginia Patent Foundation

Smart messages and alerts for an infusion delivery and management system

Method and system for providing diabetes management is provided.. .
Abbott Diabetes Care Inc.

Patient-based results display

A medical testing machine provides improved recall and display of the outcomes of tests performed by the machine. Test outcomes and other information are stored in mass storage directly accessible by the medical testing machine.
Bio-rad Laboratories, Inc.

Method for using probe based pcr detection to measure the levels of circulating demethylated beta cell derived dna as a measure of beta cell loss in diabetes

A method for measuring blood levels of β cell dna that is released upon β cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene dna, representing normal tissue and β cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin dna patterns that are present only in β cells.
Nyu Winthrop Hospital

Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
King's College London

Biomarkers

The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject.
Otago Innovation Limited

Composition and treating metabolic disorders

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof

The invention provides novel conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or r-(+)-α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or cinnamic acid, or cholic acid, or oleanolic acid, or salicylic acid, or betulinic acid, or chlorogenic acid, or caffeic acid, or bassic acid, or acetyl l-carnitine, or s-allyl cysteine sulphoxide, or s-methyl cysteine sulfoxide, or pantothenic acid, or ascorbic acid, or retinoic acid, or nicotinic acid, or biotin, or a derivative or analog thereof, and a moiety derived from berberine or l-carnitine or metformin or unsaturated fatty acid, or a derivative or analog thereof. The invention also relates to pharmaceutical compositions, methods of preparation and use of these conjugates in treating and/or preventing, for example, liver diseases or disorders, various diabetes, diabetic complications, dyslipidemia, obesity, metabolic syndromes, pre-diabetes, muscle atrophy, inflammation, and cancers.
Shenzhen Hjghtide-biopharmageutical, Ltd.

Summit Innovation Labs Llc

. .

Intrinsic chromosomal linkage and disease prediction

An improved method is the product of an exploration for ways in which to improve the success of genomic disease prediction and presents the elements of more successful prediction tools for the identification of genomic locations of disease based on: genomic labeling it loci as determined by correlated snp linkage as determined from several additional gwas (genome wide association studies) databases. The wellcome trust t2d (type 2, adult-onset, diabetes) has played a particularly important role in developing the new tools; additionally, the development of a wellness classifier, probably in part due to counter disease mutations has proven to be a powerful new tool and concept.

Use of mip-1beta inhibitors for improving angiogenesis to reduce tissue ischemia and rescue diabetic vascular disease in diabetes mellitus

The present invention relates to a use of mip-1β inhibitor for promoting angiogenesis in diabetes mellitus patients so as to improve tissue ischemia in damaged area and to prevent diabetic vasculopathy.. .
National Yang-ming University Taipei Veternas General Hospital

Substituted bridged urea analogs as sirtuin modulators

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Compositions and methods for treating retinal degradation

The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by alu rna associated with a cell, for reducing atp-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an rpe cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (amd) and wet amd, alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and duchenne muscular dystrophy..
University Of Kentucky Research Foundation

Vascular calcification prevention and treatment

The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc

Metabolic syndrome treatment

Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc

Treatment and prevention of diabetes and obesity

Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.. .

Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

Various aspects of the present invention relate to a peptide based biomaterial for visualization by shg microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (nlo) material for second harmonic generation (shg) microscopy.
Suphatchatwong Innovation Co., Ltd.

Genetically modified mesenchymal stem cell expressing klotho

A genetically modified mesenchymal stem cell (msc) includes an exogenous nucleic acid that includes a klotho encoding region operably linked to a promoter or promoter/enhancer combination. The mscs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as alzheimer's disease (ad), multiple sclerosis (ms), huntington's disease, amyotrophic lateral sclerosis (als), parkinson's disease, and schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases..
Apceth Gmbh & Co. Kg

Fiber-rich maltooligosaccharides having low glucose bioavailability, manufacture thereof and use thereof in human food and animal feed

The present invention relates to maltooligosaccharides, the content of α-1,4-glycosidic bonds of which is between 70% and 80% of the total number of 1,4-type glycosidic bonds. The invention also relates to the method for manufacturing these maltooligosaccharides.
Roquette Freres

Substituted quinolines as pde-10 inhibitors

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Compounds and methods for inducing browning of white adipose tissue

The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula i, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes..
Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences

Dermatopontin as a therapeutic for metabolic disorders

The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type i diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control..
Agency For Science, Technology And Research

Method for treating hiv

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones.
Enzo Therapeutics, Inc.

A protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine

A method for one of preventing and minimizing diabetes pathology in a mammal, comprising administering to the mammal an effective amount of n-acetylcysteine (nac).. .
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

No donors for the treatment of impaired tissue perfusion

A method for treatment of prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion, comprising administering an amino-c2-c6-alkyl nitrate, an amino-c2-c4-alkyl nitrate, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The disease or condition is a micro- and/or macro-vascular disease selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue.
Mirandapharmaceuticals Ag

Active substances and cosmetic or dermatological preparations containing said active substances for the care of the skin of patients of diabetes mellitus

Licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a or cosmetic or dermatological preparations containing licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a for the care of the skin of patients of diabetes mellitus.. .
Beiersdorf Ag

Aptamers and sensing technology used for detection of glycated hemoglobin in whole blood

High affinity dna aptamers seq id#1-8 for hba1c and thb were successfully selected using selex after 11 rounds of selection. The tested aptamers bind to hba1c with dissociation constants in the nanomolar range with the highest affinity aptamer, seq id#6, exhibiting a kd of 2.8 nm.
Alfaisal University

Devices for detection of antibodies against therapeutic drugs

Devices for detection of antibodies against therapeutic drugs (adas), in which chimeric proteins facilitate immobilization and exposure of target epitopes, are described. Results can be obtained in minutes, enabling point of care testing and/or patient self-testing, and risk assessment.

Devices, solutions and methods for sample collection related applications, analysis and diagnosis

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. Saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition.
Abogen, Inc.

Diagnostic methods, therapeutic agents and uses thereof

The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (vi): or a salt thereof.
Metabolon, Inc.

Puma, a pro-apoptotic gene, as a novel molecular biomarker for tnfalpha-induced human islet damage

P53-upregulated modulator of apoptosis (puma) is a biomarker associated with islet cell health. If puma is low, islet cells are typically healthy.
Hitachi Chemical Co., Ltd.

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.

Crystal form a of compound and preparation method thereof

The present invention relates to crystal form a of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form a.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Compositions and methods for treating obesity and hyperphagia

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes

The present disclosure describes a genome-wide transcriptional analysis of differentially expressed genes in diabetic, non-diabetic, normal and wounded tissue. The analysis allowed development of compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes, including delayed wound healing and reduced vision..
Wayne State University

Methods of preventing the occurrence of cardiovascular events

The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events..
Kowa Company, Ltd.

Methods of preventing cardiovascular events in residual risk dyslipidemic populations

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled ldl-c concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled ldl-c..
Kowa Company, Ltd.

New azabenzimidazole derivatives as agonists of the amp-activated protein kinase

The present invention relates to compounds of general formula i, wherein the group r1, x and y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

The invention relates to biomarkers associated with diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop diabetes, and methods of screening a population to identify persons at risk for developing diabetes and other pre-diabetic conditions.. .
True Health Ip Llc

Oligonucleotide sequences targeting transcription factortsc22d4 for the treatment of insulin resistance

The present invention relates to oligonucleotide inhibitors of the tsc22d4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.. .
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Glucagon antagonists

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Probes and methods for detecting amyloidogenic proteins

Disclosed herein are novel photocontrollable probes and methods for detecting aggregated forms of amyloidogenic proteins in cells, tissues, or organs of a live subject. Results of such detection may be useful for making prognosis on the subject whether he/she suffers from a neurodegenerative disease and/or diabetes mellitus..
Academia Sinica

Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine

Nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2+ charge for proper oxygen binding and carrying are further disclosed.
Entia Biosciences, Inc.

Bifidobacteria for treating diabetes and related conditions

This invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions..
Dupont Nutrition Biosciences Aps

Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

Compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.

Flip - a selective molecular target of senescent cells

The present invention relates to modulators of flip protein and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same

β-hydroxybutyric acid in combination with β-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/l), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of β-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time.
Savind, Inc.

Method, system and computer readable medium for assessing actionable glycemic risk

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (cgm) data.. .
University Of Virginia Patent Foundation

Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs

Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected.

Acylated glucagon analogues

The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Wherein the x1 denotes that the i residue is modified by either acetylation or methylation at the n-terminus; wherein x2 is l or t; wherein x3 is l or i; wherein x4 is q or e; and wherein a modified k residue (“k*”) at position 29 is modified through conjugation to the epsilon-amino group of the k-side chain with a group of the formula —x5—x6, wherein x5 is selected from the group consisting of one to four amino acids; one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and combinations of one to four amino acids and one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and x6 is a c14-c24 fatty acid. In some embodiments, the group of the formula —x5—x6 is ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γe)2-co—(ch2)x—co2h where x is 16 or 18..

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Therapeutic homodimer and uses thereof

The invention relates to therapeutic peptides and uses thereof. In particular, the invention relates to disulphide-linked homodimers useful in the treatment or prevention of diseases and conditions in mammalian subjects (such as diabetes), via transmucosal administration..

Modulators of alpha-dicarbonyl detoxification and their use for the treatment of diabetic pathologies

In various embodiments compositions and methods are provided for ameliorating a pathology characterized by elevated α-dicarbonyl compounds or prophylactically slowing or stopping the onset of said pathology in a mammal. In certain embodiments the method comprises administering to the mammal an agent that activates trpa1 in an amount sufficient to activate trpa1, and/or to ameliorate one or more symptoms of the pathology (e.g., diabetes or a complication thereof), and/or to slow or stop the onset of the pathology, and/or to lower the level of α-dicarbonyl compounds in the mammal..
Buck Institute For Research On Aging

Devices and methods for managing insulin resistance

Disclosed are devices and methods for mitigating insulin resistance in a human subject by contacting one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject with a part of a cooling device, wherein the part of the cooling device has a temperature at about 15 or less celsius degrees; cooling the one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject for a cooling period of at least 15 minutes; and performing previous two steps daily for about 14 or more days. The devices and methods may also be used to preventing, delaying or treating type 2 diabetes in a human subject or activating brown fat without incurring a sympathetic nerve-mediated cold feeling in a human subject..
Gludone Inc.

Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof

The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof.
University Of Technology, Sydney

Glucagon-receptor selective polypeptides and methods of use thereof

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon.
Intarcia Therapeutics Inc.

Compositions and methods of using islet neogenesis peptides and analogs thereof

The invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for preparing nanoprecipitates of low molecular weight peptide or protein

The present invention relates to a method for the non-denaturing preparation of peptide or protein nanoprecipitates, or of peptide or protein and metal ion nanocoprecipitales, in which said protein or said peptide has a molecular weight no higher than 20 kda, preferably no higher than 15 kda, advantageously no higher than 10 kda, and more advantageously no higher than 8 kda. Said method includes a step of preparing a mixture of an aqueous solution of peptides or proteins, a nonsolvent of the peptide or protein, and optionally a water-soluble metal salt.
Carlina Technologies

Isoquinoline derivatives as mgat2 inhibitors

The compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.. .
Merck Sharp & Dohme Corp.

Chromenone inhibitors of monocarboxylate transporters

The invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Indication mechanism for an automatic applicator, particularly for insulin

The present disclosure concerns an indication mechanism for an automatic applicator, particularly for insulin or other liquid preparations, particularly for multiple injection administration of set doses of a medicine from an exchangeable container, for example for the self-application of insulin by diabetes patients. An indication mechanism for an automatic applicator, having an assembly of at least two barrels movably coupled to each other has an indication barrel mounted on the driving barrel contains only marking on its external surface and is co-axially connected to the pull-push control nut..
Copernicus Sp. Z O.o.

Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)

Disclosed are compositions and methods for inducing sustained diabetes remission by single administration of fgf1 to the brain. The composition and methods described herein result in basal glucose clearance by using a dosage of fgf1 that is lower than that needed for systemic efficacy and is devoid of the risk of hypoglycemia and changes in body weight, food intake, hepatic glucose production, insulin secretion or insulin sensitivity..
University Of Washington

Health care

The treatment of type 2 diabetes involving the use of a regimen comprising: (a) one or more glucose-lowering drugs (g-lds) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (b) at least one non-steroidal anti-inflammatory drug (nsaid) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “mg salicylate”); (2) naproxen; and (3) ibuprofen; and (c) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (b) and (c) above..

Pteridine dione monocarboxylate transporter inhibitors

The invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Medical condition management system and methods

A system ranks pharmaceutical and other regimens for the treatment of chronic diseases (e.g., diabetes) to optimize the patient, medical, financial, and operational aspects of drug therapy using a combination of data impossible for a human to consume and process within any useful period of time. A scoring algorithm balances estimated cost, intolerance, benefit, and efficacy, using information from the patient's medical history, personal preference, drug manufacturers, clinical trial data, and other sources (e.g., insurance payment data) for every possible therapy and combination of therapies.

Metabolite biomarkers predictive of renal disease in diabetic patients

The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease..
Joslin Diabetes Center

Fas and drs are novel molecular targets of senescent cells

The present invention relates to modulators of fas and drs and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

New azabenzimidazole derivatives

The present invention relates to compounds of general formula (i), wherein r1, r2, r3, a1, a2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Heterocyclic inhibitors of monocarboxylate transporters

The invention provides compounds that inhibit monocarboxylate transporters, such as mct1 and mct4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of mct1 and/or mct4, such as cancer or type ii diabetes..
The Scripps Research Institute

Ethynyl derivatives

The present invention relates to compounds that may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Dry powder drug delivery system and methods

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity..
Mannkind Corporation

Stable pharmaceutical solution formulation of glp-1r antibody fusion protein

Disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0.01%-0.5%, and the ph value of the stable solution formulation is from 5.0 to 8.0.
Gmax Biopharm Llc.

Prevention of hypoglycaemia in diabetes mellitus type 2 patients

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) despro36exendin-4(1-39)-lys6-nh2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.. .
Sanofi-aventis Deutschland Gmbh

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Amgen Inc.

Disease prevention and alleviation by human myoblast transplantation

Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways.

Modified release compositions of epalrestat or a derivative thereof and methods for using the same

Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided..
Bionevia Pharmaceuticals Inc.

Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions

Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (lada) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid x receptor (fxr) agonist compounds, thereby activating fxr receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (lada) in the subject..
Salk Institute For Biological Studies